DSM to commercially manufacture talactoferrin for Agennix
DSM Pharmaceutical Products will manufacture the oral Dendritic Cell Mediated Immunotherapy (DCMI) talactoferrin for the Agennix at commercial levels in anticipation of positive Phase III clinical data and product approval, under a new agreement.
Talactoferrin is currently manufactured by DSM for use in ongoing clinical trials, including the FORTIS-M trial in non-small cell lung cancer (NSCLC).
DSM Pharmaceutical Products business unit DSM BioSolutions vice president Villaume Kal said this agreement recognizes intensive collaboration between DSM and Agennix.
"DSM's process design for application in large scale manufacturing largely contributed to this success, and we are delighted to continue our support of Agennix," Kal said.
The contract includes the manufacture of commercial supply of talactoferrin, process development to continue to optimize the manufacturing process, and the opportunity to significantly expand production capacity as needed.
Agennix chief medical officer and Management Board member Rajesh Malik said DSM's long-term experience with talactoferrin will be invaluable as Agennix work with them in preparation for a potential product approval and subsequent commercialization of talactoferrin.
"It is important for Agennix to put in place now the key elements of the talactoferrin supply chain, and expanding our contract with DSM is an important part of this process," Malik said.
DSM Pharmaceutical is the custom manufacturing business of Royal DSM, while Agennix is a biopharmaceutical company focused on developing novel therapies.